Αρχική World News Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in... World News Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer Από Ogkologos - 23 Ιουνίου, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... 25 Απριλίου, 2022 Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia 22 Ιουνίου, 2018 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma 28 Ιανουαρίου, 2026 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... 25 Ιουλίου, 2025 Φόρτωση περισσοτέρων HOT NEWS 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A... FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,... Virchow: The Largest Foundation Model for Computational Pathology To Date